Non S&P 500 - Weekly

Non S&P 500 - Day Ahead

ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day

Meetings - Weekly

S&P 500 Earnings - Monthly

Economic Indicators

IPO events

Dividends

Daily earnings hits & misses

Federal Reserve events

MEETINGS

DATE GMT SYMBOL EVENT TITLE 13 Nov

Accuray Incorporated Annual Stockholder Meeting 13 Nov 16:45

Acme Packet, Inc. at Needham & Co. Telecom Tech Day 13 Nov 23:30

Akorn, Inc. at Credit Suisse Group Healthcare Conf 13 Nov 17:00

Alexion Pharma.s at Credit Suisse Group Healthcare Conf 13 Nov 12:10

Alliance Financial at Sandler O'Neill&Partners Conf 13 Nov 21:00

AMERIGROUP Corp. at Credit Suisse Group Healthcare Conf 13 Nov 13:00

Anadarko Petroleum at Bank of America Conf 13 Nov 15:40

Apache Corp. at Bank of America Securities Energy Conf 13 Nov 17:30

ARRIS Group, Inc. at Needham & Co. Telecom Tech Day Conf

13 Nov 18:00

Artes Medical, Inc. Shareholders Meeting 13 Nov 15:55

Astoria Financial at Sandler O'Neill&Partners Conf 13 Nov 14:20

Atmos Energy at Bank of America Conf 13 Nov 15:00

Baker Hughes at Bank of America Conf 13 Nov 16:30

Bancorp Rhode Island at Sandler O'Neill&Partners Conf 13 Nov 19:10

BancorpSouth, at Sandler O'Neill&Partners Conf 13 Nov 3:55

Bank of NewYrk Mellon at Financial TimesCIS (Asia) Forum 13 Nov 12:45

Bank of Smithtown at Sandler O'Neill&Partners Conf 13 Nov 18:30

Barr Pharma.s, at Credit Suisse Group Healthcare Conf

13 Nov 14:20

Basic Energy Services, at Bank of America Conf 13 Nov 16:30

Berkshire Hills Bancorp at Sandler O'Neill&Partners Conf

13 Nov 19:30

Bill Barrett at Bank of America Conf 13 Nov 23:30

Bio-Reference Laboratories at Credit Suisse Grp Conf 13 Nov 19:10

Boston Scientific at Sandler O'Neill&Partners Conf 13 Nov 18:10

BRIGHAM EXPLORATION CO at Bank of America Conf 13 Nov 20:10

Cabot Oil & Gas at Bank of America Conf 13 Nov 20:50

Cal Dive Intl. at Bank of America Securities Energy Conf 13 Nov 21:05

Capital City Bank Group at Sandler O'Neill&Partners Conf

13 Nov 15:55

CapitalSource Inc at Sandler O'Neill&Partners Conf 13 Nov 19:10

Cardinal Financial at Sandler O'Neill&Partners Conf 13 Nov 16:00

Centene Corp. at Credit Suisse Group Healthcare Conf 13 Nov 19:00

Chemed Corp. at Credit Suisse Group Healthcare Conf 13 Nov 20:10

Cheniere Energy at Bank of America Securities Energy Conf 13 Nov 18:00

Cisco Systems Annual Shareholders Meeting 13 Nov 18:00

Citigroup at Sandler O'Neill&Partners Conf 13 Nov 12:45

Comerica at Sandler O'Neill&Partners Conf 13 Nov 14:45

Community Trust at Sandler O'Neill&Partners Conf 13 Nov 15:00

CONCHO RES INC at Bank of America Securities Energy Conf 13 Nov 20:45

Concurrent Computer at Needham&Co. TechDay Conf 13 Nov 13:40

Continental Resources, at Bank of America Conf 13 Nov 18:30

Covance at Credit Suisse Group Healthcare Conf 13 Nov 18:30

Credit Suisse Group Healthcare Conf 13 Nov 17:30

Cytokinetics, Inc. at Credit Suisse Group Healthcare Conf 13 Nov 15:00

DeVry Shareholders Meeting 13 Nov 21:00

Dyax Corp. at Credit Suisse Group Healthcare Conf 13 Nov 14:00

Electronic Arts at BMO Capital Markets Conf 13 Nov 19:55

ENCORE BANCSHARES INC at Sandler O'Neill&Partners Conf 13 Nov 17:30

Ensco Intl. at Bank of America Securities Energy Conf

13 Nov 14:20

EOG Resources, at Bank of America Conf 13 Nov 17:00

Eric May Luncheons 13 Nov 16:00

Express Scripts, at Credit Suisse Group Healthcare Conf 13 Nov 19:55

F.N.B. at Sandler O'Neill&Partners Conf 13 Nov 13:20

Fifth Third Bancorp at Sandler O'Neill&Partners Conf 13 Nov 14:45

First Financial Ohio at Sandler O'Neill&Partners Conf 13 Nov 19:55

First Financial Hldngs at Sandler O'Neill&Partners Conf 13 Nov 13:00

First Horizon National at Merrill Lynch Conf 13 Nov 18:00

First Midwest Bancorp at Sandler O'Neill&Partners Conf 13 Nov 19:10

First Niagara Financial at Sandler O'Neill&Partners Conf

13 Nov 21:40

First Place Financial at Sandler O'Neill&Partners Conf 13 Nov 12:10

FirstMerit at Sandler O'Neill&Partners Conf 13 Nov 12:10

Flushing Financial at Sandler O'Neill&Partners Conf 13 Nov 20:50

Fmc Tech., Inc. at Bank of America Securities Energy Conf 13 Nov 13:30

FTI Consulting at Argyle Executive Ldrshp Forum 13 Nov 16:00

G&K Services Shareholders Meeting 13 Nov 15:00

Genentech, Inc. at Credit Suisse Group Healthcare Conf 13 Nov 18:50

GeoMet, Inc at Bank of America Securities Energy Conf 13 Nov 14:30

GLU MOBILE INC at BMO Capital Markets Conf 13 Nov 3:15

Google at Piper Jaffray Global Internet Summit 13 Nov 20:10

GulfMark Offshore at Bank of America Conf 13 Nov 21:05

Hancock Hldng Co. at Sandler O'Neill&Partners Conf 13 Nov 19:15

Harmonic at Needham & Co. Telecom Tech Day Conf 13 Nov 21:30

Healthways at Credit Suisse Group Healthcare Conf 13 Nov 17:30

Hornbeck Offshore Services, at Bank of America Conf 13 Nov 13:50

ICF Intl. at SMi Grp Financial Modelling in Oil&Gas Conf

13 Nov 18:30

IdentiPHI Invstr Roundtable Meetgs for Shrhldrs-Chicago 13 Nov 8:05

Intel Corp. at DisplaySearch Taiwan TV Supply Chain Conf

13 Nov 19:00

Intl. Game Tech. at BMO Capital Markets Conf 13 Nov 8:30

Intersil at DisplaySearch Taiwan TV Supply Chain Conf 13 Nov 17:30

Johnson & Johnson at Credit Suisse Group Healthcare Conf 13 Nov 18:20

KOHLBERG CAPITAL CORP at Argyle Executive Ldrshp Forum 13 Nov 22:00

Laboratory of America at Credit Suisse Global Conf 13 Nov 16:30

LifePoint Hospitals, at Credit Suisse Grp Conf 13 Nov 14:30

Magellan Health Services at Credit Suisse Grp Conf 13 Nov 14:00

Marsh & McLennan at Standard&Poors Bermuda Conf 13 Nov 14:40

Marshall & Ilsley at Merrill Lynch Conf 13 Nov 21:00

MB Financial at Sandler O'Neill&Partners Conf COPYRIGHT

Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

MMMM

Company Highlights

Cardiovascular

--  In August, at the European Society of Cardiology 2008 Congress, in
    September, at the 2008 Annual Heart Failure Society of America (HFSA)
    Conference and in October at the 13th Annual Meeting of the Japanese Heart
    Failure Society, Cytokinetics presented data from an ongoing Phase IIa
    clinical trial evaluating CK-1827452 administered intravenously to patients
    with stable heart failure. These interim analyses indicate that, to date,
    CK-1827452 has been well-tolerated in stable heart failure patients over a
    range of plasma concentrations. In addition, the most recent data presented
    showed statistically significant correlations between CK-1827452 plasma
    concentration and increases in systolic ejection time, stroke volume,
    fractional shortening, cardiac output, and ejection fraction. Cytokinetics
    has completed enrollment of the fourth cohort of this trial and has
    initiated dosing of patients in the fifth cohort.

--  During the quarter, Cytokinetics announced the completion of a
    protocol-defined interim safety analysis in an ongoing Phase IIa clinical
    trial evaluating the safety and tolerability of both an intravenous and an
    oral formulation of CK-1827452 in patients with ischemic cardiomyopathy and
    angina. The safety analysis allowed for the progression from Cohort 1 to
    Cohort 2 in this trial. Cytokinetics recently completed enrollment of the
    second and last cohort of this trial.

--  During the quarter, Cytokinetics initiated a third Phase IIa clinical
    trial designed to evaluate an intravenous formulation of CK-1827452 in
    patients with stable heart failure undergoing clinically indicated coronary
    angiography in the cardiac catheterization laboratory. In addition, at the
    2008 Annual HFSA Conference, an investigator presented a poster on the
    design of this Phase IIa clinical trial which is intended to test the
    hypothesis that CK-1827452 may improve cardiac function and hemodynamics
    without significantly altering myocardial oxygen consumption and thus
    improve cardiac efficiency. Cytokinetics anticipates data will be available
    from this trial in 2009.

Oncology

--  In September, at the 2008 American Society of Clinical Oncology Breast
    Cancer Symposium, Cytokinetics presented interim results from the Phase I
    portion of its Phase I/II clinical trial of ispinesib, a novel kinesin
    spindle protein (KSP) inhibitor, as monotherapy administered as a first-
    line treatment for chemotherapy-naive patients with locally advanced or
    metastatic breast cancer. Interim data demonstrated that this drug
    candidate was well-tolerated when administered as a 1-hour intravenous
    infusion on days 1 and 15 of a 28-day cycle with the most frequent adverse
    event being neutropenia. The best responses observed to date were
    investigator-reported tumor reductions of 30% or greater in the sum of the
    target lesion diameter, reported in 3 patients. One of these patients had
    an investigator-reported partial response according to the Response
    Evaluation Criteria in Solid Tumors (RECIST). Cytokinetics continues to
    enroll and dose-escalate patients in the Phase I portion of this trial.

--  Earlier this month at the EORTC-NCI-AACR International Symposium on
    Molecular Targets and Cancer Therapeutics, a poster was presented
    containing preclinical and clinical data on SB-743921, a novel KSP
    inhibitor. The authors concluded that SB-743921 demonstrated potent
    activity in preclinical models of diffuse large B-cell lymphoma both in
    vitro and in vivo, which provides additional scientific rationale for
    continuing the currently ongoing Phase I/II clinical trial in patients with
    Hodgkin or non-Hodgkin lymphoma. Cytokinetics continues to enroll and dose-
    escalate patients in the Phase I portion of this trial.

--  Also at the EORTC-NCI-AACR symposium, Cytokinetics' strategic partner,
    GlaxoSmithKline (GSK), presented three posters containing preclinical or
    clinical data on GSK-923295, a novel and selective inhibitor of centromere-
    associated protein E. The first preclinical poster determined that positron
    emission tomography using 2-[18F]fluoro-s-deoxy-d-glucose imaging may
    provide a means of evaluating pharmacodynamic activity in patients treated
    with GSK-923295. The second preclinical poster concluded that GSK-923295
    has dose-dependent pharmacodynamic activity in Colo205 human xenografts. A
    third poster summarized clinical data from an ongoing Phase I dose
    escalation trial for GSK-923295. The authors concluded that this drug
    candidate has been well-tolerated at the doses evaluated to date. GSK
    continues to enroll and dose-escalate patients in this Phase I trial.

Corporate

--  In September, the company announced a realignment of its workforce and
    operations in line with a strategic reassessment of its research and
    development activities and corporate objectives. The company is now
    focusing research activities to its muscle biology programs while
    continuing to advance ongoing clinical trials in heart failure and cancer.
    To implement this plan, the company reduced its workforce by approximately
    29% and discontinued early research activities directed to oncology.

Financials

Revenues from research and development collaborations for the third quarter of 2008 were $3.1 million, compared to $4.1 million for the same period in 2007. Revenues for the third quarter of 2008 and 2007 were primarily derived from the company's collaboration and option agreement with Amgen, Inc.

Total research and development (R&D) expenses in the third quarter of 2008 were $13.5 million, compared to $13.2 million for the same period in 2007. The increase in R&D expenses in the third quarter of 2008, compared to the same period in 2007, was primarily due to increased spending for clinical outsourcing costs, offset in part by lower personnel expenses.

Total general and administrative (G&A) expenses for the third quarter of 2008 were $3.8 million, compared to $4.1 million for the same period in 2007. The decrease in G&A expenses in the third quarter of 2008, compared to the same period in 2007, was primarily due to lower patent and legal fees and personnel expenses.

Cytokinetics also reported results of its operations for the nine months ended September 30, 2008. Revenues from research and development collaborations for the nine months ended September 30, 2008 were $9.3 million, compared to revenues of $10.5 million for the same period in 2007. The decrease in collaborative research revenues for the first nine months of 2008, as compared to the same period in 2007, was primarily the result of lower revenue from the company's collaboration and license agreement with GSK.

Total R&D expenses for the nine months ended September 30, 2008 were $42.5 million, compared to $39.4 million for the same period in 2007. The increase in R&D expenses in the first nine months of 2008, compared to the same period in 2007, was primarily due to higher clinical outsourcing and laboratory costs.

Total G&A expenses for the nine months ended September 30, 2008 were $12.2 million, compared to $12.6 million for the same period in 2007. The decreased spending in the first nine months of 2008, compared to the same period in 2007, was primarily due to lower legal fees, which was partially offset by an increase in spending for outside services and personnel expenses.

The net loss for the nine months ended September 30, 2008, which included $2.5 million in restructuring charges, was $45.5 million, or $0.92 per share, compared to a net loss of $35.6 million, or $0.76 per share, for the same period in 2007.

Update on Financial Guidance for 2008

The company anticipates its full year 2008 cash operating expenses to be between $76.0 and $81.0 million, including severance costs and its current assumptions associated with costs related to its clinical trials and consultants. As a result of this restructuring, the company's cash operating expenses are anticipated to decrease between $12.0 and $16.0 million in 2009, as compared to our cash operating expenses in 2008.

Company Milestones for 2008

Cardiovascular

CK-1827452

--  In November, Cytokinetics plans to present data from its ongoing Phase
    IIa trial of CK-1827452 in patients with stable heart failure at the Annual
    Meeting of the American Heart Association in New Orleans, Louisiana.

--  In the fourth quarter of 2008, Cytokinetics anticipates that data will
    be available from its ongoing Phase IIa trial of CK-1827452 in patients
    with ischemic cardiomyopathy and angina.

Oncology

Ispinesib (SB-715992)

--  In December, Cytokinetics plans to present additional data from the
    ongoing Phase I portion of its open-label, non-randomized Phase I/II
    clinical trial designed to evaluate ispinesib as monotherapy administered
    as a first-line treatment for chemotherapy-naive patients with locally
    advanced or metastatic breast cancer at the 31st Annual San Antonio Breast
    Cancer Symposium in San Antonio, Texas.

SB-743921

--  In December, Cytokinetics plans to present additional data from the
    Phase I portion of its ongoing Phase I/II clinical trial of SB-743921 as a
    potential treatment of patients with Hodgkin or non-Hodgkin lymphoma at the
    2008 Annual American Society of Hematology Meeting in San Francisco,
    California.

Corporate

--  In the fourth quarter of 2008, Cytokinetics anticipates providing the
    required clinical data from its CK-1827452 Phase IIa clinical trials
    program to Amgen in order to inform the potential exercise of Amgen's
    option under the companies' strategic alliance.

Conference Call and Webcast Information

Members of Cytokinetics' management team will review third quarter results via a webcast and conference call today at 4:30 PM Eastern Time. The webcast can be accessed in the Investor Relations section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call is also accessible via telephone to investors, members of the news media and the general public by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 57552468.

An archived replay of the webcast will be available via Cytokinetics' website until November 14, 2008. The replay will also be available via telephone by dialing (800) 642-1687 (United States and Canada) or (706) 645-9291 (International) and typing in the passcode 57552468 from October 30, 2008 at 5:30 PM Eastern Time until November 14, 2008.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is conducting the Phase I portion of a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-naive patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting the Phase I portion of a Phase I/II clinical trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an option for the joint development and commercialization of ispinesib and SB-743921. GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' financial guidance, including expected cash operating expenditures, revenues and R&D and G&A expenses for 2008; Cytokinetics' and its partners' research and development activities, including the conduct, design, focus, scope, enrollment, progress and results of Cytokinetics' and its partners' research and development activities, including clinical trials and the anticipated timing for the presentation or availability of data from clinical trials; the anticipated benefits of Cytokinetics' September 2008 restructuring; Cytokinetics' ability to leverage its expertise in muscle biology; Cytokinetics' provision to Amgen of clinical data to inform Amgen's potential exercise of its option under the companies' collaboration and option agreement; and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval or production of Cytokinetics' drug candidates that could slow or prevent clinical development, product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, including, but not limited to, difficulties or delays due to political instability in countries where clinical trials of Cytokinetics' drug candidates are being conducted, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; GSK may decide to postpone or discontinue development activities for GSK-923295; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change and others may introduce products or alternative therapies for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to Amgen's and GSK's decisions as to whether to exercise their respective options and the timing and receipt of payments, including option fees, milestones and royalties on future potential product sales, under Cytokinetics' collaboration agreements with Amgen and GSK. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

                Condensed Statement of Operations
          (in thousands, except share and per share data)
                          (unaudited)
                              Three Months Ended      Nine Months Ended
                             September   September   September   September
                             30, 2008    30, 2007    30, 2008    30, 2007
                            ----------  ----------  ----------  ----------
Revenues:
   Research and development $       67  $    1,072  $       93  $    1,337
   License revenues              3,058       3,058       9,175       9,175
                            ----------  ----------  ----------  ----------
      Total revenues             3,125       4,130       9,268      10,512
                            ----------  ----------  ----------  ----------
Operating Expenses:
   Research and development     13,519      13,217      42,480      39,430
   General and
    administrative               3,826       4,113      12,235      12,611
   Restructuring Charges         2,492           -       2,492           -
                            ----------  ----------  ----------  ----------
      Total operating
       expenses                 19,837      17,330      57,207      52,041
                            ----------  ----------  ----------  ----------
Operating loss:                (16,712)    (13,200)    (47,939)    (41,529)
   Interest and other
    income                         571       2,055       2,819       6,418
   Interest and other
    expense                       (118)       (176)       (398)       (531)
                            ----------  ----------  ----------  ----------
Net loss                    $  (16,259) $  (11,321) $  (45,518) $  (35,642)
                            ==========  ==========  ==========  ==========
Net loss per common share -
 basic and diluted          $    (0.33) $    (0.24) $    (0.92) $    (0.76)
Weighted average shares
 used in computing net loss
 per common share - basic
 and diluted                49,415,937  47,460,424  49,358,705  47,039,631
                          Condensed Balance Sheet
                              (in thousands)
                                (unaudited)
                                               September 30,  December 31,
                                                   2008           2007
                                               -------------  -------------
Assets
Cash and cash equivalents                      $      70,636  $     116,564
Short term investments                                     -          3,175
Other current assets                                   2,147          2,277
                                               -------------  -------------
Total current assets                                  72,783        122,016
Long term investments                                 18,230         20,025
Property and equipment, net                            5,899          7,728
Restricted investments                                 2,750          5,167
Other assets                                             381            434
                                               -------------  -------------
Total assets                                   $     100,043  $     155,370
                                               =============  =============
Liabilities and stockholders' equity
Current liabilities                            $      24,467  $      26,448
Long-term obligations                                 18,272         29,006
Stockholders' equity                                  57,304         99,916
                                               -------------  -------------
Total liabilities and stockholders' equity     $     100,043  $     155,370
                                               =============  =============

Cytokinetics, Incorporated
Christopher S. Keenan (Investors and Media)
Director, Investor Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.

"The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure" will be presented in a Cardiovascular Seminar (#117) entitled "Translational Trials and Strategies: First in Man" on Sunday, November 9, 2008, from 5:15 PM - 6:45 PM Central in Rooms 275-277 of Ernest N. Morial Convention Center. The presentation will be made by John Cleland, MD, FACC, FRCP, FESC, Professor of Cardiology, Castle Hill Hospital, University of Hull, United Kingdom.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is conducting the Phase I portion of a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-naive patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting the Phase I portion of a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an option for the joint development and commercialization of ispinesib and SB-743921. GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the planned presentation at the American Heart Association meeting of results from Cytokinetics' ongoing clinical trial with CK-1827452 and the potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Christopher S. Keenan
Director, Investor Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.

He is also scheduled to present at the 17th Annual Credit Suisse Annual Global Healthcare Conference on Thursday, November 13, 2008 at 10:30 a.m. Mountain Time at The Arizona Biltmore Hotel in Phoenix, Arizona.

Interested parties may access the live audio webcast of these presentations and replays by visiting the Investors Relations section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors Relations section of Cytokinetics' website for two weeks following the completion of each of the events.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is conducting the Phase I portion of a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-naive patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting the Phase I portion of a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an option for the joint development and commercialization of ispinesib and SB-743921. GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Christopher S. Keenan
Director, Investor Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.